Testing Menu
T Cell Elispot IFN-γ & IL-2
This detailed analysis answers three critical questions:
What organism is causing this infection?
Is the infection actively detected by the immune system?
How severe is it?
By mapping these immune dynamics, T Cell ELISPOT testing provides healthcare providers with a clear, actionable snapshot of a patient’s immune status. This empowers the development of tailored treatment strategies, whether addressing acute infections, chronic conditions like Cytomegalovirus or Epstein-Barr virus, or guiding post-treatment recovery, enhancing patient outcomes with unparalleled clarity and reliability.
i-Labs has an unmatched portfolio within the US for ELISPOT testing. T Cell ELISPOT testing is a sophisticated immunological assay developed in the 1980s, designed to evaluate antigen-specific T cell responses with unmatched precision. Initially utilized in the 1990s to predict viral reactivation risks before liver transplants, it has evolved into a vital tool for assessing immune dynamics across a spectrum of infections. The process begins with whole blood, from which peripheral blood mononuclear cells (PBMCs) are isolated and plated in a specialized cell culture dish.
These cells are then stimulated with specific antigens under optimized conditions at 37°C, ensuring effective antigen presentation by antigen-presenting cells within the PBMCs. This triggers TH-1 T cells to secrete IFN-γ, indicating active immune defense and infection severity, and central memory T cells to produce IL-2. The key to understanding the usefulness of this testing method is that both measured antigen-specific T cell subsets require having seen the antigen (pathogen) recently in the lymph node. Each cytokine release forms a distinct spot on the assay’s membrane, with each spot representing a single antigen-specific T cell response, enabling precise enumeration of TH-1 and central memory T cell subsets.
T CELL ELISPOT: IFN-γ & IL-2 (Chlamydia pneumoniae)
This test is exclusive to i-Labs in the U.S, identifying active infections, gauging their intensity, assessing immune response suitability. This assay delivers reliable, actionable insights, enabling providers to track immune changes and develop targeted treatment plans, enhancing patient outcomes for Chlamydia pneumoniae infections with precision and clarity.
Employing enzyme-linked immunospot technology, the T Cell ELISPOT IFN-γ & IL-2 assay for Chlamydia pneumoniae at i-Labs offers a precise assessment of T cell responses to this respiratory bacterial pathogen. Isolating peripheral blood mononuclear cells through enzyme-linked immunospot technology, the test stimulates them with Chlamydia pneumoniae antigens and quantifies IFN-γ and IL-2 secretion.
IFN-γ, produced by TH-1 T cells, reflects active immune engagement, crucial for evaluating infection severity. IL-2 is produced by central memory T cells and helps us detect more inconspicuous infections.
T CELL ELISPOT: IFN-γ & IL-2 (Borrelia spp. – Lyme)
This assay confirms active infection, assesses its severity, and evaluates if the immune response is appropriate. As the only U.S. lab offering this test, i-Labs provides reliable, actionable data, empowering providers to monitor immune dynamics and craft precise treatment strategies for effective Lyme disease management.
Our T Cell ELISPOT IFN-γ & IL-2 assay for B. burgdorferi, B. afzelii, or B. garinii offers a robust analysis of T cell responses to this complex tick-borne pathogen that causes Lyme disease. The test isolates peripheral blood mononuclear cells, stimulates them with Borrelia antigens, and measures IFN-γ and IL-2 secretion. IFN-γ, produced by TH-1 T cells, highlights active immune engagement, critical for determining the intensity of Lyme infection. IL-2, secreted by central memory T cells, allows us to detect more subtle infections.
T CELL ELISPOT: IFN-γ & IL-2 (Chlamydia pneumoniae)
This test is exclusive to i-Labs in the U.S, identifying active infections, gauging their intensity, assessing immune response suitability. This assay delivers reliable, actionable insights, enabling providers to track immune changes and develop targeted treatment plans, enhancing patient outcomes for Chlamydia pneumoniae infections with precision and clarity.
Employing enzyme-linked immunospot technology, the T Cell ELISPOT IFN-γ & IL-2 assay for Chlamydia pneumoniae at i-Labs offers a precise assessment of T cell responses to this respiratory bacterial pathogen. Isolating peripheral blood mononuclear cells through enzyme-linked immunospot technology, the test stimulates them with Chlamydia pneumoniae antigens and quantifies IFN-γ and IL-2 secretion.
IFN-γ, produced by TH-1 T cells, reflects active immune engagement, crucial for evaluating infection severity. IL-2 is produced by central memory T cells and helps us detect more inconspicuous infections.
T CELL ELISPOT: IFN-γ & IL-2 (Borrelia miyamotoi)
This test identifies active infections, gauges their intensity, and evaluates immune response suitability. Exclusive to i-Labs in the U.S., this assay provides precise, reliable insights, enabling providers to track immune progression and develop tailored treatment plans, enhancing patient recovery with clarity and confidence.
The i-Labs ELISPOT IFN-γ & IL-2 assay for Borrelia miyamotoi at iLabs delivers a targeted evaluation of immune responses to this tick-borne relapsing fever pathogen. Employing advanced enzyme-linked immunospot technology, it isolates peripheral blood mononuclear cells, stimulates them with Borrelia miyamotoi antigens, and quantifies IFN-γ and IL-2 release. When IFN-γ is secreted by TH-1 T cells, this signals robust immune activation, key to assessing acute infection severity. IL-2 is produced by central memory T cells and is used to detect milder infections.
T CELL ELISPOT: IFN-γ & IL-2 (Bartonella henselae)
This test identifies active infections, evaluates their intensity, and confirms if the immune response is appropriate. Exclusive to i-Labs in the U.S., it delivers precise, reliable data, enabling providers to track immune changes and design targeted therapies. This clear immune snapshot supports informed clinical decisions, optimizing patient recovery.
The assay for Bartonella henselae at i-Labs provides a sophisticated tool to evaluate immune responses to this bacterial pathogen. Using enzyme-linked immunospot technology, it isolates peripheral blood mononuclear cells, stimulates them with Bartonella henselae antigens, and quantifies IFN-γ and IL-2 production. When TH-1 T cells release IFN-γ, it indicates active immune defense, essential for assessing infection severity. IL-2, released from central memory T cells, helps us identify low-level infections.
T CELL ELISPOT: IFN-γ & IL-2 (Babesia microti)
This test determines if an infection is active and its severity. Unique to i-Labs in the U.S., this assay provides a reliable snapshot of immune dynamics, enabling providers to monitor infection stages and tailor precise treatment plans, enhancing patient outcomes with actionable insights.
The T CELL ELISPOT: IFN-γ & IL-2 assay for Babesia microti at iLabs delivers a detailed assessment of T cell responses to this tick-borne parasite. Employing enzyme-linked immunospot technology, it isolates peripheral blood mononuclear cells, stimulates them with Babesia microti antigens, and measures IFN-γ and IL-2 release. IFN-γ, secreted by TH-1 T cells, reflects active immune engagement, crucial for gauging infection intensity. IL-2, produced by central memory T cells, helps us to identify subtle infections.
T Cell ELISPOT IFN-γ & IL-2 (Ehrlichia)
This assay confirms active Ehrlichia infection, assesses its intensity. Exclusive to i-Labs in the U.S., it provides precise, reliable data, enabling providers to monitor immune progression and design tailored treatment strategies, optimizing patient outcomes for Ehrlichia infections.
The ELISPOT assay for Ehrlichia from i-Labs delivers a targeted analysis of T cell responses to this tick-borne bacterial pathogen. The test isolates peripheral blood mononuclear cells using enzyme-linked immunospot technology, then stimulates them with Ehrlichia antigens, and measures the production of IFN-γ and IL-2. IFN-γ, secreted by TH-1 T cells, indicates active immune defense, essential for evaluating the severity of infection.
T Cell ELISPOT: IFN-γ & IL-2 (Mycoplasma pneumoniae)
This test equips providers with a clear immune profile by confirming active infection, assessing its intensity, and evaluating if the immune response is appropriate. This actionable data supports tailored treatment strategies, enabling precise management of Mycoplasma pneumoniae infections and optimizing patient recovery with focused insights.
The T Cell ELISPOT IFN-γ & IL-2 assay for Mycoplasma pneumoniae, exclusive to i-Labs in the U.S., provides a sharp lens on T cell responses to this respiratory bacterial pathogen. Through enzyme-linked immunospot technology, peripheral blood mononuclear cells are stimulated with Mycoplasma pneumoniae antigens, measuring IFN-γ and IL-2 release.
IFN-γ, from TH-1 T cells, highlights active immune defense, key to determining infection severity. IL-2, secreted by central memory T cells, provides a way to detect less intense infections that are harder to detect.
T Cell ELISPOT: IFN-γ & IL-2 (Rickettsia)
This test confirms active Rickettsia infection, measures its intensity, and assesses immune response suitability. The resulting data empowers providers to track immune dynamics and design precise treatment plans, enhancing patient outcomes for Rickettsia-related conditions with clear, actionable insights.
Offered solely by i-Labs in the U.S., the T Cell ELISPOT IFN-γ & IL-2 assay for Rickettsia delivers a focused evaluation of T cell responses to this tick-borne bacterial pathogen. Using enzyme-linked immunospot technology, it stimulates peripheral blood mononuclear cells with Rickettsia antigens and quantifies IFN-γ and IL-2 secretion. IFN-γ, produced by TH-1 T cells, signals active immune defense, critical for gauging infection severity. Central memory T cells secrete IL-2, providing a signal for the detection of more subtle infections.
T Cell ELISPOT IFN-γ & IL-2 (Epstein-Barr Virus – Lytic & Latent Antigens)
i-Labs’ Epstein-Barr Virus (EBV) test identifies whether EBV is driving patient symptoms by analyzing T cell responses, indicating if the infection is active or latent. The test distinguishes between EBV’s four stages, specifically targeting Stage 3 and Stage 4.
Stage 3, latent infection, is a silent persistence in B cells (another immune cell) with limited antigen expression (meaning that the virus is in hiding). It is associated with some autoimmune diseases, cancer development, and Chronic Fatigue Syndrome ME/CFS.
Stage 4, chronic lytic infection, is active replication, immune activation, and viral shedding. It is associated with PTLD, HIV-related lymphomas, CAEBV, and IBD flares. Both stages can be distinguished and detected with our specific testing. Regularly checking these values can help reduce long-term risks.
T Cell ELISPOT: IFN-γ & IL-2 (Cytomegalovirus – IE-1 & pp65 Antigens)
This test identifies active CMV infection, gauges its intensity, and evaluates the suitability of the immune response. Exclusive to i-Labs in the U.S., this assay provides reliable, actionable data, helping providers track immune responses and develop targeted treatment plans, enhancing outcomes for CMV-related conditions.
The T Cell ELISPOT IFN-γ & IL-2 assay for Cytomegalovirus (CMV) targeting IE-1 and pp65 antigens at i-Labs offers a precise evaluation of T cell responses to this common viral pathogen. Employing enzyme-linked immunospot technology (ELISPOT), it isolates peripheral blood mononuclear cells, stimulates them with CMV IE-1 and pp65 antigens, and quantifies IFN-γ and IL-2 secretion.
IFN-γ, produced by TH-1 T cells, reflects active immune engagement, key to assessing infection severity. Central memory T cells produce IL-2, which we use to detect less conspicuous infections.
T CELL ELISPOT: IFN-γ & IL-2 (Aspergillus Mix 1 & Mix 2)
This test identifies whether an Aspergillus infection is active, gauges its severity, and evaluates the appropriateness of the immune response. This detailed snapshot empowers providers to tailor treatment plans with confidence. i-Labs has a unique test portfolio in the U.S., with this test leveraging cutting-edge technology to deliver reliable, actionable data, enabling providers to monitor immune dynamics and guide patients toward recovery.
The T CELL ELISPOT: IFN-γ & IL-2 assay for Aspergillus Mix 1 & Mix 2 at i-Labs offers healthcare providers a precise tool to assess immune responses to Aspergillus infections. Utilizing advanced enzyme-linked immunospot technology, this test measures T cell activity by detecting IFN-γ and IL-2 secretion, providing critical insights into the immune system’s current state.
Whether addressing acute or persistent infections, this assay equips providers with a clear roadmap for precision care, enhancing clinical decision-making with unparalleled specificity.
T CELL ELISPOT: IFN-γ & IL-2 (Candida albicans)
This assay confirms active Candida infection, evaluates its intensity, and assesses if the immune response is appropriate. Unique to i-Labs in the U.S., the test delivers reliable, actionable data, empowering providers to monitor immune dynamics and design precise treatment strategies, optimizing outcomes for patients with Candida albicans infections.
The iLabs assay for Candida albicans provides a detailed evaluation of T cell responses to this opportunistic fungal pathogen. Using enzyme-linked immunospot technology, the test isolates peripheral blood mononuclear cells, stimulates them with Candida albicans antigens, and measures their production of IFN-γ and IL-2.
The release of IFN-γ by TH-1 T cells indicates active immune defense, essential for assessing the severity of fungal infection. IL-2, secreted by central memory T cells, indicates low-level infections.
T Cell ELISPOT: IFN-γ & IL-2 (HSV-1 & HSV-2)
The test pinpoints active HSV infections, measures their intensity, and assesses how appropriate the immune response is. This reliable, actionable data aids providers in monitoring immune changes and crafting precise treatment plans, enhancing patient outcomes for HSV-related conditions with clarity and precision.
Exclusively offered by i-Labs in the U.S., the T Cell ELISPOT: IFN-γ & IL-2 assay for Herpes Simplex Virus (HSV-1 & HSV-2) delivers a detailed assessment of T cell responses to these prevalent herpesviruses. Employing enzyme-linked immunospot technology, it stimulates peripheral blood mononuclear cells with HSV-1 and HSV-2 antigens, quantifying IFN-γ and IL-2 production. IFN-γ, secreted by TH-1 T cells, reveals active immune engagement, vital for gauging infection severity. IL-2, produced by central memory T cells, indicates sustained immune memory, showing if the infection is active or in a controlled, latent state.
T Cell ELISPOT: IFN-γ & IL-2 (HHV-6)
Available only at i-Labs in the U.S., the T Cell Elispot: IFN-γ & IL-2 assay for Human Herpesvirus 6 (HHV-6) offers a robust analysis of T cell responses to this pervasive herpesvirus. By leveraging enzyme-linked immunospot technology, it stimulates peripheral blood mononuclear cells with HHV-6 antigens and measures IFN-γ and IL-2 secretion. IFN-γ, released by TH-1 T cells, indicates active immune defense, essential for evaluating infection severity.
Confirming active infection, assessing its intensity, and evaluating immune response suitability equips providers to track immune dynamics and develop targeted treatment strategies, optimizing patient outcomes for HHV-6-related conditions.
T CELL ELISPOT: IFN-γ & IL-2 (SARS-CoV-2)
This assay identifies active SARS-CoV-2 infection and evaluates its intensity. It can detect antigen-specific immune responses to low amounts of pathogen still present and help identify if a viral reservoir of SARS-CoV-2 is still present in a patient with long-haul symptoms. The test delivers precise, reliable insights, enabling providers to monitor immune dynamics and tailor targeted treatment strategies, optimizing patient recovery from COVID-19 with unparalleled clarity.
The T CELL ELISPOT: IFN-γ & IL-2 assay for SARS-CoV-2 at iLabs provides a cutting-edge analysis of T cell responses to the virus causing COVID-19. We use enzyme-linked immunospot technology to isolate peripheral blood mononuclear cells, stimulate them with SARS-CoV-2 antigens, and measure IFN-γ and IL-2 production. IFN-γ, secreted by TH-1 T cells, signals active immune defense, crucial for assessing the severity of viral infection. IL-2, from central memory T cells, indicates long-term immune memory.
T Cell ELISPOT: IFN-γ & IL-2 (Varicella Zoster Virus – Lytic & Latent)
Exclusively at i-Labs in the U.S., the T Cell ELISPOT: IFN-γ & IL-2 assay for Varicella Zoster Virus (VZV), targeting lytic and latent antigens, provides a nuanced view of T cell responses to this herpesvirus. Employing enzyme-linked immunospot technology, it stimulates peripheral blood mononuclear cells with VZV antigens, measuring IFN-γ and IL-2 production. IFN-γ, secreted by TH-1 T cells, reflects active immune engagement, vital for assessing infection intensity.
By confirming active infection, evaluating its severity, and assessing immune response this test offers a clear immune snapshot. Providers can leverage these insights to craft targeted therapies, optimizing management of VZV-related conditions like shingles with precision.
T CELL ELISPOT: IFN-γ & IL-2 (Babesia duncani)
This test determines whether an infection is active, its severity, and the suitability of the immune response. Exclusive to i-Labs in the U.S., it provides reliable data to track immune shifts, empowering providers to craft targeted treatment strategies and guide patient recovery with clarity.
The T CELL ELISPOT: IFN-γ & IL-2 assay for Babesia duncani at iLabs offers a precise window into T cell responses against this tick-borne pathogen. Using advanced enzyme-linked immunospot technology, it isolates peripheral blood mononuclear cells from whole blood, re-stimulates them with a species-specific Babesia duncani single antigen, and quantifies IFN-γ and IL-2 secretion.
IFN-γ, produced by TH-1 T cells, signals active immune defense against infection, which is critical for assessing the intensity of acute infections. IL-2 is produced from central memory T cells. Both T cell subsets require having seen the antigen in the lymph node recently to secrete IFN-γ and IL-2.
T Cell ELISPOT: IFN-γ & IL-2 (Hepatitis C Virus – Core & E2NS2-5 Peptides)
Unique to i-Labs in the U.S., the T Cell ELISPOT: IFN-γ & IL-2 assay for Hepatitis C Virus (HCV), targeting core and E2NS2-5 peptides, offers a detailed assessment of T cell responses to this chronic viral pathogen. Using enzyme-linked immunospot technology, peripheral blood mononuclear cells are stimulated with HCV antigens, quantifying IFN-γ and IL-2 secretion.
IFN-γ, released by TH-1 T cells, signals active immune defense, crucial for evaluating infection severity. IL-2, produced by central memory T cells, indicates sustained immune memory, revealing whether the infection is active or controlled. This assay confirms active HCV infection, measures its intensity.
These insights enable providers to monitor immune dynamics and develop precise treatment strategies, enhancing patient outcomes for Hepatitis C-related conditions with clear, actionable data.
T Cell ELISPOT Fungal & Lung Infections
i-Labs’ T Cell ELISPOT: Fungal and Lung Infections Panel empowers healthcare providers to accurately diagnose and manage patients with suspected fungal or pulmonary infections, such as those caused by Aspergillus, Candida, Pneumocystis, or bacterial pathogens like Mycobacterium. This comprehensive panel detects immune responses to multiple pathogens, enabling providers to identify the root cause of symptoms like chronic cough, fatigue, or respiratory distress.
By pinpointing active infections, the test supports tailored treatment plans, optimizes antimicrobial or antifungal therapy, and monitors treatment efficacy, reducing the risk of persistent or recurrent infections and improving patient outcomes.
Using enzyme-linked immunospot (ELISPOT) technology, this assay measures antigen-specific T cell responses by quantifying IFN-γ and IL-2 secretion from peripheral blood mononuclear cells stimulated with antigens specific to fungal and lung pathogens. For example, elevated TH-1 T cell activity indicates an active immune response to a specific pathogen, while low activity suggests no current infection. IL-2 T cell activity suggests a more subtle infection. The panel’s multi-pathogen approach ensures thorough evaluation of complex respiratory infections, guiding precise clinical decisions.
T Cell ELISPOT Lyme & Co-Infection
i-Labs’ T Cell ELISPOT: Lyme and Coinfections Panels equip healthcare providers with a powerful diagnostic tool to detect immune responses to Lyme disease and associated coinfections, enabling precise, individualized treatment plans. Ticks frequently carry multiple pathogens, such as Borrelia burgdorferi, Bartonella, Babesia, and Anaplasma, necessitating comprehensive testing to identify complex infections driving patient symptoms like fatigue, joint pain, or neurological issues.
By assessing T cell activity, this panel helps providers confirm active infections, distinguish between Lyme and coinfections, gauge how appropriately the immune system is responding, and monitor treatment efficacy, optimizing patient outcomes through targeted interventions and reducing the risk of chronic complications.
Utilizing enzyme-linked immunospot (ELISPOT) technology, this assay measures antigen-specific T cell responses by detecting IFN-γ and IL-2 secretion from peripheral blood mononuclear cells stimulated with Lyme-specific antigens and coinfection antigens. For example, elevated responses from TH-1 T cells, with upregulated cytokines, indicate active infection, while elevated IL-2 T cell response indicates a less intense infection. The panel’s ability to test for multiple tick-borne pathogens ensures comprehensive evaluation, addressing the complexity of tick-borne diseases.
3148 Neuro-HPA Axis Test
Patients with anxiety, depression, chronic fatigue, sleep issues, stress-related disorders, neuroinflammation, or PTSD.
What It Tests:
#3133 Urine Neurotransmitters: Epinephrine, Dopamine, Norepinephrine, Serotonin, GABA, Glutamate, Histamine, 5-HIAA, Quinolinic acid, Dopac
#3146 Saliva Cortisol: 4-point adrenal function assessment
#3147 Saliva Melatonin: Evening collection for sleep/immune health
Why Choose It?
This panel evaluates the neuro-HPA axis-immune pathways critical for stress, fatigue, and mental health. It’s a simple add-on for patients undergoing bloodwork, requiring no shaking or freezing, and provides actionable insights for personalized care.
Who Benefits?
Patients with symptoms of anxiety, depression, mood disorders, chronic fatigue, sleep disturbances, stress-related conditions, or neuroinflammation.
What It Tests:
Urine Neurotransmitters: Epinephrine, Dopamine, Norepinephrine, Serotonin, GABA, Glutamate, Histamine, 5-HIAA, Quinolinic acid, Dopac
Why Choose It?
This test assesses key neurotransmitters influencing mental health, stress response, and neurological function. It provides actionable insights for personalized treatment plans, with a simple urine collection process requiring no special handling.
Who Benefits?
Patients experiencing chronic fatigue, stress-related disorders, sleep disturbances, adrenal dysfunction, or symptoms of anxiety and depression.
What It Tests:
Saliva Cortisol: 4-point collection to evaluate adrenal function throughout the day.
Why Choose It?
This test assesses the Hypothalamus-Pituitary-Adrenal (HPA) axis via cortisol levels, providing insights into stress response and adrenal health. Its simple saliva collection process requires no special handling, enabling actionable, personalized treatment plans.
Who Benefits?
Patients with sleep disturbances, immune dysregulation, or stress-related conditions.
What It Tests:
Saliva Melatonin: Evening collection to assess melatonin levels for sleep and immune health.
Why Choose It?
This test evaluates melatonin production, critical for regulating sleep and supporting immune function. Its straightforward saliva collection process requires no special handling, providing actionable insights for personalized patient care.
T Cell ELISPOT Viral Infections
i-Labs’ T Cell ELISPOT: Viral Infections Panel enables healthcare providers to accurately diagnose and manage viral infections, such as Epstein-Barr Virus (EBV), CMV, and other pathogens that may be driving symptoms like fatigue, sore throat, swollen glands, or neurological issues. By detecting lytic or latent viral infections, this panel helps providers identify the cause of complex symptoms, tailor antiviral or supportive therapies, and monitor treatment progress.
This assay employs enzyme-linked immunospot (ELISPOT) technology to measure antigen-specific T cell responses by detecting IFN-γ and IL-2 secretion from peripheral blood mononuclear cells stimulated with viral antigens (e.g., EBV, CMV). By using multiple specific subsets of antigens we are able to distinguish in what cycle a viral infection is on. It is possible this way to distinguish viral reactivation and if latent or lytic or both viral particles are currently present in a patient.
It can be very important for health care providers to monitor and check in the in which part of the cycle these Herpes virus family members are in, as different stages of chronic reactivation are associated with causing serious issues like chronic fatigue, some cancers, gut problems and in certain cases Immune exhaustion.
Cytokines
i-Labs’ Cytokines Test provides healthcare providers with a detailed analysis of a patient’s immune response, facilitating accurate diagnosis and management of inflammatory, infectious, or autoimmune conditions. By quantifying key inflammatory cytokines, this test identifies immune dysregulation underlying symptoms like chronic fatigue, joint pain, or systemic inflammation.
Providers can leverage these insights to design targeted therapies, such as anti-inflammatory or immunomodulatory treatments, and monitor therapeutic outcomes, enhancing patient care. The test’s precise cytokine profiling supports data-driven decisions, reducing the risk of chronic disease progression and optimizing individualized treatment plans.
Using serum cytokine measurements (e.g., TNF-α, IFN-γ, IL-1β, IL-6, IL-8) provides insights into the body's inflammatory and immune status, helping assess immune activation and monitor disease progression (e.g., autoimmune disorders, infections, cancers). This test complements T cell ELISPOT and other assays for comprehensive immune evaluation and provides context about tissue inflammation vs inflammation caused by infection.
Food Sensitivity IgG
i-Labs’ Food Sensitivity IgG Blot Test equips healthcare providers with a robust tool to identify food intolerances driving patient symptoms, such as gastrointestinal distress, fatigue, or inflammation. By detecting IgG antibody responses to specific food antigens, this test helps providers pinpoint trigger foods, enabling personalized dietary interventions to alleviate symptoms and improve patient outcomes. The test’s detailed profiling supports precise treatment plans, enhances patient compliance through targeted dietary guidance, and aids in monitoring therapeutic progress, reducing the risk of chronic inflammation or related conditions.
With our Food Sensitivity IgG Blot Test we qualitatively assesses 108 relevant IgG antibody responses to food-specific antigens. IgG antibodies, unlike IgM, reflect either a current immune response or past exposure, providing insight into chronic or delayed food sensitivities. For example, a positive IgG result for specific food antigens suggests an immune response that may contribute to symptoms, guiding dietary elimination strategies. This test complements clinical evaluations, offering actionable data for tailored patient care.
Functional Immune Cell Flow Cytometry
i-Labs offers advanced Immune Assessment Testing, designed to evaluate a patient’s immune system responsiveness and activity in the context of infections. This cutting-edge diagnostic tool quantifies the functionality of CD4 and CD8 T cells, measures effector cytokine production per T cell, and provides critical insights for healthcare providers.
For example, a patient with low CD4 (5%) and CD8 (13%) T cell activity and minimal cytokine production may indicate no active infection, confirming negative results, such as for Lyme disease. Conversely, elevated responses (e.g., 21% CD4, 32% CD8 T cells) to Borrelia antigens suggest an active immune response to infection. High activity against CMV antigens (22% CD4, 54% CD8) with elevated effector molecules indicates an active immune system.
In cases of high immune activity (29% CD4, 52% CD8) without specific a known specific infection, further investigation for other infections is recommended. This comprehensive testing empowers providers to tailor interventions based on individualized immune profiles.
CD57+ Natural Killer Cell Test
The CD57+ Natural Killer (NK) Cell Test from i-Labs empowers healthcare providers to optimize treatment decisions for patients with suspected chronic infections or malignancies by providing critical insights into immune function.
This flow cytometry-based assay quantifies CD57+ NK cells, a subset expressing the CD57, CD56 and CD16 surface marker, and these cells represent fully differentiated NK cells. These cells are which is linked to clinical prognosis in solid tissue cancers and are shown to be low in the blood during acute or reactivations of certain viruses such as SARS-CoV2 and Epstein Barr.
Reduced CD57+ NK cell counts—this test helps providers tailor therapeutic strategies, enhancing patient outcomes through personalized care. When combined with other diagnostic tools, especially infections that are known to be associated with low CD57+ NK cells counts (e.g., immune assessments or antigen-specific assays), and clinical symptoms, the test offers valuable data to guide decision-making.
Immune Assessment Testing
Benefits to Providers
i-Labs Immune Assessment Testing equips healthcare providers with precise insights into a patient’s immune function, enabling tailored treatment strategies for chronic infections. By evaluating the strength, weakness, and responsiveness of the immune system, this test helps identify whether a patient is actively fighting an infection, guiding accurate diagnosis and intervention.
For instance, it can confirm negative results (e.g., Lyme disease) or detect active infections (e.g., CMV reactivation), allowing providers to adjust therapies, monitor progress, and reduce long-term complications. The test’s detailed immune profiling supports data-driven decisions, enhancing patient outcomes through personalized care.
This is a cell-based assay that stimulates antigen-independent CD4+ and CD8+ T cell responses and quantifies the outcome. The results will tell if antigen-experienced T cells (CD44 high) are prepared for activity and how well they are producing effector molecules.
For example, a patient with low activity (5% CD4, 13% CD8 T cells, minimal cytokines) indicates no active infection, confirming negative Lyme (or other pathogenic infection) T cell results. Conversely, elevated responses (e.g., 21% CD4, 32% CD8 active) with upregulated cytokines signal an active immune system with a productive effector molecule response. This test is a very helpful supportive test and is recommended to be used in parallel with antigen-specific ELIspot testing. In combination with our other tests it can be answered what infection is present (ELIspot), how bad it is (ELIspot), and if the immune system is responding appropriately (Immune Assessment) are the T cells active, and how well they are producing their effector molecules.
Immune Senescence Testing
i-Labs Immune Senescence Testing empowers healthcare providers to assess age-related or disease-driven declines in immune function, optimizing management of patients with chronic infections or compromised immunity. By identifying immune senescence—reduced immune responsiveness due to aging T cell populations—providers can tailor interventions, such as immune-modulating therapies, to improve patient resilience.
The frequency of CD8⁺CD56⁺Granzyme B⁺ T cells in peripheral blood tends to increase with age, reflecting the cumulative impact of chronic immune stimulation and the gradual remodeling of the immune system. In older adults, these cytotoxic T cell subsets are more prevalent and often display features of terminal differentiation, such as reduced proliferative capacity and heightened cytotoxicity. This shift contributes to immune senescence, characterized by a decline in adaptive immune responsiveness and an increase in pro-inflammatory activity. Therefore, measuring the proportion of CD8⁺CD56⁺Granzyme B⁺ T cells in peripheral blood offers a practical biomarker for assessing age-related immune changes and the functional status of the aging immune system.
This test helps predict infection susceptibility, guide preventive strategies, and monitor treatment efficacy, particularly in patients with chronic diseases like Lyme or viral infections, enhancing long-term outcomes through proactive care.
Unlike Immune Assessment Testing, which focuses on active infection, this assay evaluates long-term immune competence, identifying patients at risk for recurrent infections or poor recovery. Results guide targeted interventions to restore immune function.
Immune Exhaustion Test
i-Labs’ Immune Exhaustion Test assesses PD-1 expression on CD4+ and CD8+ T cells. PD-1 is a protein that T cells express in immune exhaustion. This test evaluates fatigue in chronic conditions like viral infections and autoimmune diseases, measuring its impact on infection response. Combined with our T cell ELISPOT assays and immune assessments, it offers a holistic view to guide targeted therapies for patients with complex symptoms.
Long Haul Viral
i-Labs’ T Cell ELISPOT: Long-Haul Viral Panel empowers healthcare providers to diagnose and manage complex chronic viral conditions, including Post-Acute Sequelae of SARS-CoV-2 (Long-Haul COVID), EBV, and CMV, which drive symptoms like chronic fatigue, myalgia, or neurological issues. For patients at risk of developing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), this panel identifies specific viral triggers, allowing for tailored antiviral, anti-inflammatory, or immunomodulatory treatments.
This assay utilizes enzyme-linked immunospot (ELISPOT) technology to detect antigen-specific T cell responses by measuring the secretion of IFN-γ and IL-2 by antigen-specific T cells in response to viral antigens (e.g., SARS-CoV-2, EBV, CMV). The immune assessment adds clarity for the healthcare provider to know if the immune system is responding appropriately, depending on the infection and reactivation status of the tested viruses.
Elevated T cell activity (e.g., 22% CD4, 54% CD8 with high cytokines) indicates an active immune system, while low activity (e.g., 5% CD4, 13% CD8) suggests the immune system is resting.
We offer serum cytokines and also cortisol as an additional add-on for healthcare providers to look beyond viral infection and check for tissue inflammation.
Telomere PCR
Telomere Length Test
i-Labs’ Telomere Length Test uses a sensitive qPCR-based method to measure average telomere length in white blood cells. Telomeres are protective DNA sequences at chromosome ends that shorten with each cell division, serving as key aging markers linked to chronic disease risk and reduced regenerative capacity. This advanced assay empowers healthcare providers to monitor the impact of lifestyle or therapeutic strategies, enabling tailored interventions to optimize patient longevity with precise insights.
